Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The results were shown in multiple posts on X. A clinical trial to prove the safety and efficacy of Elon Musk's brain implant is ongoing, with 12 people currently using the devices.
The all-cash deal is expected to be finalized in April 2026. With this divestment of its ambulatory labs, Tennessee-based Community Health Systems said it will be better able to focus on its core patient care business.
Artera, a company that utilizes AI for patient communications, made the announcement while revealing it has achieved $100 million in annual revenue. Its products use AI for follow-ups after patient care, in addition to supporting clinical decisions.
Authorities allege the pharmacy chain gave patients more insulin than prescribed and then billed Medicare and Medicaid for the full amounts. This allegedly occurred for more than a decade.
The FDA has OK’d two subsidiaries of Los Angeles-based RadNet to sell medical AI software—one product for diagnosing breast cancer, the other for streamlining MRI prostate reporting workflows.
A radiology practice with a national footprint has picked Fujifilm Healthcare Americas to supply workflow management software and related services across the practice’s growing enterprise.
The news comes after the New Hampshire Attorney General's Office issued a report that it objected to the merger on the basis that it violates New Hampshire law.
Of 1,000 patients injected with corticosteroids under fluoroscopic guidance at an academic medical center over a 4½-year period, only 10 experienced serious complications within a year.
More than 40% of Americans are generally OK with the thought of AI reading their chest x-rays. Moreover, some 12.3% are very comfortable with the prospect.
U.S. healthcare is now a solid week into the CT contrast shortage of ’22, and common themes are emerging in adaptations at local hospitals and imaging centers.